| Exciting News for Researchers: Tap into the potential of multi-dimensionality with HUMANOID™!
Hey there, innovative minds! 🌟
Are you tired of the artifacts of 2D culture? Looking for a breakthrough way to fast-track your research and unlock new discoveries that can maintain relevance in the 3D context of human tissues? The UC San Diego HUMANOID™ Center has got you covered! As the trailblazer in human organoid-based models, and located at the heart of the main campus in the George Palade Laboratories for Cellular and Molecular Medicine, HUMANOID™ is transforming the way we approach drug safety and efficacy testing, biomarker discovery, or just about anything foundational with translational potential. Here's a rundown of how HUMANOID™ can supercharge your research and take your work to the next level!
Visit our Service Tracking and Recharge Portal
|
|
|
-
We biobank organoids that are derived from adult-stem cells and primary cells isolated from diseased and healthy tissues; this preserves both genetic and epigenetic factors that influence the inherited risk factors and environmental interactions which drive diseases.
-
Our deep and diverse biobank (see below) is rigorously evaluated using computational approaches for precision in matching model vs disease.
- We offer training, support, consultations, and optimized media formulation to maintain affordability and improve access and reproducibility.
-
We work closely with subject matter experts (physician-scientists) in each disease area alongside computational scientists to achieve relevance and precision in our models.
- Besides cancers and pre-cancer states, we prioritize fibrotic, metabolic, and immune diseases.
-
By introducing Phase '0' human trials which test efficacy (not just toxicity) using multi-variate analyses, HUMANOID aims to identify and terminate underperforming drug programs early, thereby saving valuable time and resources.
|
|
|
-
Inflammatory Bowel Disease: Over 350 unique Crohn’s Disease and Ulcerative Colitis subjects; many lines come with corresponding myofibroblasts from the same subject. Selected lines have undergone comprehensive phenotype, genotype, and transcriptome analyses. All lines feature thorough metadata, encompassing patient demographics, clinicopathologic behavior, histology reports, treatment information, and, where applicable, patient response.
-
Hereditary Cancer (Predisposition) Syndromes: Familial adenomatous polyposis (FAP), juvenile polyposis syndrome (JPS), Lynch syndrome (HPNCC), and Peutz-Jeghers syndrome (PJS). Includes repeat biopsies from the same subjects for longitudinal studies and multiple organ locations in some subjects, such as colon, small intestine, gastric, and esophageal tissues. All patient-derived organoids come with pathology reports and insights into their diagnosis-defining mutation.
- Foregut Diseases (pre-cancer): Barrett’s esophagus, eosinophilic esophagitis, gastric intestinal metaplasia, GERD, as well as healthy controls.
-
Lung Inflammation, Fibrosis, and Cancer: Several unique subjects, some of whom have matching tumor and normal organoids. PDO lines have been extensively characterized for retaining all 5 epithelial cell types in culture, essential for modeling alveolar diseases. These lines are valuable for studying lung inflammation (COVID-19, bacterial), lung fibrosis, the effects of anti-fibrotic therapies using EVs and small molecules, and immunotherapy impact. Information includes smoker status but not tumor genotype.
- Cancer Patient-Derived Organoids (PDOs): Several cancer PDO lines, representing various cancers (colon, biliary, pancreas, gastric, and esophagus). Some of these are from the ATCC, the Broad Institute and Columbia University. These lines are available for researchers to conduct organoid-based cancer studies, emphasizing our motto, we bank, so that you can avoid the hassle and just focus on your planned studies!".
|
|
|
Our vision goes beyond HUMANOID™ alone! We've joined forces within the Institute for Network Medicine (iNetMed) to leverage the collaborative research community that was modeled after the Broad Institute. Simply put, the HUMANOID is to the Institute what the Cancer Cell Line Encyclopedia (CCLE) is to the Broad Institute, except it is not restricted to cancers and it is dedicated to 3D biology in adult stem cell derived organoids (as opposed to 2D cultures). HUMANOID's team reverse-engineers human organoid-based models of 'disease-in-a-dish,' built up or down in complexity with additional dimensions (e.g., stromal and immune cells, microbes, toxins, etc.) to enable rapid testing of drug safety and efficacy across a diverse human population. Our approach is all about leveraging 3D primary human cells from various organs and tissues, paving the way for groundbreaking discoveries, while staying grounded by setting benchmarks for precision disease modeling.
Our models are computationally vetted through a rigorous process that seeks to objectively show the degree of "match" between model vs. disease. We prioritize human primary cells and adult stem cell-based models because we know that you care not just about genetics, but also about epigenetics—and you need a dynamic model whose complexity supports that potential. Most importantly, we all care about moving past the artifacts of immortalized 2D cultures so that we can find lasting solutions for improving human lives. Although HUMANOID biobanks only human organoids, we provide training and services to help you grow murine organoids.
Finally, by partnering with several research facilities on this campus, e.g., the Genomics Center at the Institute for Genomic Medicine (IGM), histology core at the LJI, Agilent Center for Excellence (Agilent CoE), Electron Microscopy, and imaging centers such as the School of Medicine Microscopy Core and the Nikon Imaging Center (NIC) we seek to provide you a one-stop shop for you to ask and answer exciting questions.
|
|
|
How Can HUMANOID™ Help Your Research? |
- Test Hypotheses: Use human organoids to validate your research ideas and push boundaries.
-
Drive Discoveries: Tap into our cutting-edge models to uncover new treatments, novel biomarkers and even therapeutic interventions (small molecules, antibodies, CRISPR/RNA interference).
- Test Drug Toxicity & Efficacy: Get precise results that could accelerate your journey from the lab to real-world applications.
|
|
|
Unsubscribe | Privacy Policy | Submit Feedback
This email was sent to prghosh@ucsd.edu.
To continue receiving our emails, add us to your address book.
9500 Gilman Dr | La Jolla, CA 92093 US
Copyright 2024 Regents of the University of California. All rights reserved.
|
|
|
|
